Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Gains from Investment Securities (2018 - 2025)

Dna X (SONM) has disclosed Gains from Investment Securities for 8 consecutive years, with $79715.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Gains from Investment Securities fell 16.96% year-over-year to $79715.0, compared with a TTM value of $79715.0 through Jun 2025, up 50.41%, and an annual FY2024 reading of $41874.0, up 5200.51% over the prior year.
  • Gains from Investment Securities was $79715.0 for Q2 2025 at Dna X, up from $56000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.5 million in Q3 2023 and bottomed at -$233000.0 in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $228062.3, with a median of $86179.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 2116.34% in 2022, while the deepest fall reached 417.78% in 2022.
  • Year by year, Gains from Investment Securities stood at -$45000.0 in 2021, then crashed by 417.78% to -$233000.0 in 2022, then surged by 154.51% to $127000.0 in 2023, then tumbled by 67.03% to $41874.0 in 2024, then soared by 90.37% to $79715.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for SONM at $79715.0 in Q2 2025, $56000.0 in Q1 2025, and $41874.0 in Q4 2024.